Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

NCT02218606 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Abiraterone acetate 1000 mg po daily
DRUG: Cabazitaxel 25 mg/m2 IV
DRUG: prednisone 5 mg po BID

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]